Publication Name	World Journal of Gastroenterology
Manuscript ID	9601
Country

Received	2014-02-20 13:44
Peer-Review Started	2014-02-20 15:44
To Make the First Decision	2014-03-13 18:57
Return for Revision	2014-03-20 08:43
Revised	2014-04-10 13:55
Second Decision	2014-06-23 10:07
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-06-23 10:17
Articles in Press	2014-06-23 10:33
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-09-04 20:07
Publish the Manuscript Online	2014-09-19 19:25

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Masayoshi Yada, Akihide Masumoto, Kenta Motomura, Hirotaka Tajiri, Yusuke Morita, Hideo Suzuki, Takeshi Senju and Toshimasa Koyanagi
Funding Agency and Grant Number
Corresponding Author	Akihide Masumoto, MD, PhD, Department of Hepatology, Iizuka Hospital, 3-83 Yoshio-machi, Iizuka, Fukuoka 820-8505, Japan. amasumotoh1@aih-net.com
Key Words	Hand-foot syndrome; Hepatocellular carcinoma; Indicator of efficacy; Sorafenib; Time to progression
Core Tip	Clinical factors influencing the efficacy of sorafenib for treating patients with advanced hepatocellular carcinoma (HCC) were evaluated in this study. As only the size of the largest tumor correlated significantly with overall survival, analyses were focused on factors affecting time to progression (TTP). Sorafenib was more effective for treating patients with extrahepatic compared to intrahepatic advanced HCC. The occurrence of hand-foot syndrome as an adverse event significantly correlated with increased TTP and may therefore be a useful indicator for adjusting the dose of sorafenib to improve its effectiveness and the health-related quality of life of patients with advanced HCC.
Publish Date	2014-09-19 19:25
Citation	Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol 2014; 20(35): 12581-12587
URL	http://www.wjgnet.com/1007-9327/full/v20/i35/12581.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i35.12581

Full Article (PDF)	WJG-20-12581.pdf
Full Article (Word)	WJG-20-12581.doc
Manuscript File	9601-Review.docx
Answering Reviewers	9601-Answering reviewers.pdf
Copyright License Agreement	9601-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	Ethics_Committee_20140219172608.pdf
Non-Native Speakers of English Editing Certificate	9601-Language certificate.pdf
Peer-review Report	9601-Peer review.pdf
Scientific Misconduct Check	9601-CorssCheck.jpg
Scientific Editor Work List	9601-Scientific editor work list.pdf